Patents Assigned to UCL BUSINESS LTD
-
Publication number: 20210125367Abstract: A computer implemented method of identifying contacts of an electrode implanted into the brain of a subject via bolts through the skull of the subject, based on an image of the subject, the method comprising: identifying at least one bolt region of the image corresponding to a bolt; identifying one or more contact regions of the image corresponding to electrode contacts; determining contact regions associated with an identified bolt region by searching for identified contact regions, the search being performed based on a search axis extending from the identified bolt region, the direction of the search axis being determined based on the identified bolt region.Type: ApplicationFiled: April 30, 2019Publication date: April 29, 2021Applicant: UCL BUSINESS LTDInventors: Alejandro GRANADOS, Rachel SPARKS, Sebastien OURSELIN
-
Publication number: 20210088549Abstract: A whispering gallery mode inertial sensor includes a whispering gallery mode resonator; an evanescent coupler configured to couple with an evanescent field of the resonator so that light is transmitted to and received from the resonator by the coupler; a displacement sensor configured to determine a displacement of the resonator according to the light received from the resonator by the coupler; a controller configured to determine an acceleration and/or rate of rotations experienced by the resonator based on the displacement of the resonator, the controller being further configured to apply a restoring force to the resonator in a closed feedback loop based on the displacement of the resonator in order to maintain a predetermined mechanical state of the resonator; and a timing sensor configured to determine a timing signal based on an optical frequency comb produced by the resonator.Type: ApplicationFiled: June 20, 2018Publication date: March 25, 2021Applicant: UCL Business Ltd.Inventors: Ying Lia Li, Peter Francis Barker
-
Patent number: 10947538Abstract: The invention relates to an oligonucleotide that supresses the expression of an allele carrying a dominant mutation that causes hereditary sensory neuropathy type I (HSN1), wherein the suppression takes place through hybridisation of said oligonucleotide to the DNA of said allele or to an RNA transcript of said allele, and which either does not suppress the expression of a wild-type allele not containing the dominant mutation or suppresses the expression of said wild-type allele to a lesser extent than it suppresses the expression of the dominant mutant allele; and also pharmaceutical compositions comprising oligonucleotides of the invention and treatments of HSN1 using such oligonucleotides.Type: GrantFiled: March 8, 2017Date of Patent: March 16, 2021Assignee: UCL BUSINESS LTDInventors: Francesco Muntoni, Haiyan Zhou, Mary Reilly
-
Patent number: 10933142Abstract: The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R1—H which comprises a first functional moiety of formula F1 to a second functional moiety of formula F2 wherein X, X?, Y, R1, F1 and F2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.Type: GrantFiled: December 16, 2019Date of Patent: March 2, 2021Assignee: UCL BUSINESS LTDInventors: Mark Smith, Stephen Caddick, James Baker, Vijay Chudasama
-
Publication number: 20210052173Abstract: A sensor is provided for measuring a flow of a fluid in a physiological environment, such as within a vessel of a human or animal subject. The sensor comprises an interrogation light guide extending from a proximal end to a distal end of the sensor. The interrogation light guide is configured to transmit interrogation light to, and receive reflected interrogation light from, the distal end of the sensor. The sensor further comprises an excitation light guide configured to transmit excitation light to the distal end of the sensor. The excitation light is provided for heating the fluid (directly or indirectly). The sensor further comprises a sensing element located at the distal end of the sensor. The sensing element comprises at least two etalons for reflecting interrogation light back along the interrogation light guide towards the proximal end of the sensor. Each etalon has a respective optical path length and further has at least one reflective surface external to the interrogation light guide.Type: ApplicationFiled: January 22, 2019Publication date: February 25, 2021Applicant: UCL BUSINESS LTDInventors: Adrien DESJARDINS, Malcolm FINLAY, Ioannis PAPAKONSTANTINOU, Charles Alexander MOSSE, Joanna M. COOTE, Sacha NOIMARK, Erwin ALLES
-
Patent number: 10925943Abstract: The present invention provides a polypeptide having the formula: St-R1-S1-Q-S2-R2 wherein St is a stalk sequence which, when the polypeptide is expressed at the surface of a target cell, causes the R and Q epitopes to be projected from the cell surface; R1 and R2 are a Rituximab-binding epitopes each having the an amino acid sequence selected from the group consisting of SEQ ID No. 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16 or a variant thereof which retains Rituximab-binding activity; S1 and S2 are optional spacer sequences, which may be the same or different; and Q is a QBEnd1O-binding epitope having the amino acid sequence shown as SEQ ID No. 2 or a variant thereof which QBEnd1O-binding activity. The invention also provides a nucleic acid sequence encoding such a polypeptide and uses thereof in adoptive cell transfer.Type: GrantFiled: April 11, 2013Date of Patent: February 23, 2021Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Brian Philip
-
Publication number: 20210002648Abstract: The present invention relates to analgesic treatments to reduce pain through use of an inhibitor of fatty-acid amide hydrolase pseudogene (FAAH-OUT).Type: ApplicationFiled: February 12, 2019Publication date: January 7, 2021Applicant: UCL BUSINESS LTDInventors: James John Cox, Devjit Srivastava
-
Patent number: 10881613Abstract: The present invention relates to fumarate polymersomes. The polymersomes are capable of targeting immune cells and then hydrolysing to release the immunomodulatory compound fumarate. The polymersomes can thus be used methods for the treatment of prevention of diseases, including immune diseases such as multiple sclerosis and psoriasis.Type: GrantFiled: March 17, 2017Date of Patent: January 5, 2021Assignee: UCL BUSINESS LTDInventor: Giuseppe Battaglia
-
Patent number: 10874611Abstract: The present invention relates to polymersomes that contain an encapsulated drug and that exhibit chemotaxis in response to a chemical stimulus. The chemotactic polymersomes can be targeted in vivo to a location of therapeutic interest with high specificity and selectivity. The present invention also provides related pharmaceutical compositions and therapeutic methods.Type: GrantFiled: January 27, 2017Date of Patent: December 29, 2020Assignee: UCL BUSINESS LTDInventor: Giuseppe Battaglia
-
Patent number: 10864163Abstract: The invention relates to methods for attaching therapeutic agents to structures produced by thermally induced phase separation as well as methods for coating devices and producing multi-layered microspheres.Type: GrantFiled: December 22, 2014Date of Patent: December 15, 2020Assignee: UCL Business LTDInventor: Richard Michael Day
-
Patent number: 10842885Abstract: The present invention relates to polynucleotides comprising a Factor IX nucleotide sequence, wherein the Factor IX nucleotide sequence comprises a coding sequence that encodes a Factor IX protein or fragment thereof and wherein a portion of the coding sequence is not wild type. The present invention further relates to viral particles comprising a recombinant genome comprising the polynucleotide of the invention, compositions comprising the polynucleotides or viral particles, and methods and uses of the polynucleotides, viral particles or compositions.Type: GrantFiled: August 20, 2018Date of Patent: November 24, 2020Assignee: UCL Business LTDInventors: Amit Nathwani, Jenny McIntosh
-
Patent number: 10829547Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.Type: GrantFiled: October 16, 2018Date of Patent: November 10, 2020Assignees: Eisai R&D Management Co., Ltd., UCL Business LTDInventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
-
Patent number: 10828263Abstract: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ?m or less.Type: GrantFiled: December 6, 2017Date of Patent: November 10, 2020Assignee: UCL Business LtdInventors: Mohan Edirisinghe, Ming Wei Chang, Eleanor Stride
-
Publication number: 20200330591Abstract: The invention provides an antibody or fragment thereof that specifically binds to human Lrg1.Type: ApplicationFiled: December 27, 2019Publication date: October 22, 2020Applicant: UCL Business LtdInventors: Vineeta TRIPATHI, Rose SHERIDAN, John GREENWOOD, Stephen MOSS
-
Patent number: 10792336Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding a Factor VIII protein, wherein a B domain portion of the Factor VIII protein is encoded by a nucleotide sequence between 90 and 111 nucleotides in length and has an amino acid sequence that is at least 85% identical to SEQ ID NO: 4 which comprises six asparagine residues. Also provided is a Factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating Haemophilia Haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.Type: GrantFiled: July 10, 2018Date of Patent: October 6, 2020Assignees: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, UCL BUSINESS LTDInventors: Amit Nathwani, Jenny McIntosh, Edward Tuddenham, Andrew Davidoff
-
Patent number: 10792395Abstract: This invention relates to a method of producing a decellularised tissue scaffold which comprising treating a sample of tissue with an osmotic reagent and a detergent whilst subjecting the tissue sample to oscillation with a displacement of 1 mm or more and a frequency of 3 Hz or more during these treatment steps. This method may be useful in producing acellular scaffolds that maintain the 3-D architecture and extracellular matrix composition and morphology of the native tissue.Type: GrantFiled: July 29, 2016Date of Patent: October 6, 2020Assignee: UCL Business LtdInventors: Giuseppe Mazza, Walid Al-Akkad Abu Zeina, Massimo Pinzani
-
Patent number: 10781162Abstract: The invention relates to a crystalline diethylamine tetrathiomolybdate salt (DEA-TTM). The invention also relates to methods for producing the crystalline DEA-TTM salt of the invention. The invention also relates to pharmaceutical compositions comprising the crystalline DEA-TTM salt of the invention. The invention also relates to the use of the crystalline DEA-TTM salt of the invention in the treatment of the human or animal body, in particular its use in treatment of a condition requiring reduced metabolism of an organ or the whole body of a patient, by administering to a patient in need thereof a therapeutically effective amount of the crystalline DEA-TTM salt.Type: GrantFiled: October 20, 2017Date of Patent: September 22, 2020Assignee: UCL Business LtdInventors: Alex Peter Dyson, Daniel Gooding, Joanne Holland
-
Patent number: 10780059Abstract: A layered body comprising: a core region; at least one intermediate layer disposed around the core region; and an outer layer disposed around the at least one intermediate layer, wherein at least one of the at least one intermediate layers comprises a gas, the layered body having at least one dimension, measured across the body and through the core region, of 100 ?m or less.Type: GrantFiled: December 6, 2017Date of Patent: September 22, 2020Assignee: UCL Business LtdInventors: Mohan Edirisinghe, Ming Wei Chang, Eleanor Stride
-
Patent number: 10752665Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL) which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.Type: GrantFiled: February 26, 2015Date of Patent: August 25, 2020Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Kwee Yong, Lydia Lee, Neil Chaplin, Ben Draper
-
Patent number: 10745715Abstract: The present invention relates to a producer cell which expresses a tagging protein at the cell surface, such that retroviral vectors produced by the cell are tagged with the tagging protein, wherein the tagging protein comprises: i) a binding domain which binds to a capture moiety ii) a spacer; and iii) a membrane targeting domain such that, when incorporated a retroviral vector, the tagging protein facilitates purification of the retroviral vector from cellular supernatant via binding of the tagging protein to the capture moiety. The present invention also relates to a retroviral vector comprising such a producer cell-derived tagging protein.Type: GrantFiled: August 28, 2015Date of Patent: August 18, 2020Assignee: UCL BUSINESS LTDInventors: Martin Pulé, Leila Mekkaoui, Gordon Weng-Kit Cheung